Surgical treatment of primary breast cancer in the neoadjuvant setting
Background Neoadjuvant chemotherapy (NACT) is a standard treatment option for primary
operable breast cancer when adjuvant chemotherapy is indicated. Methods This article …
operable breast cancer when adjuvant chemotherapy is indicated. Methods This article …
Current status of pharmacologic therapies in patient blood management
LT Goodnough, A Shander - Anesthesia & Analgesia, 2013 - journals.lww.com
Patient blood management1, 2 incorporates patient-centered, evidence-based medical and
surgical approaches to improve patient outcomes by relying on the patient's own …
surgical approaches to improve patient outcomes by relying on the patient's own …
Effects of erythropoiesis-stimulating agents on fatigue-and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and …
Background: Erythropoiesis-stimulating agents (ESAs) reduce the need for red blood cell
transfusions; however, they increase the risk of thromboembolic events and mortality. The …
transfusions; however, they increase the risk of thromboembolic events and mortality. The …
[HTML][HTML] Outcome after neoadjuvant chemotherapy in elderly breast cancer patients–a pooled analysis of individual patient data from eight prospectively randomized …
G von Waldenfels, S Loibl, J Furlanetto, A Machleidt… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Methods From 1998 to 2010, eight prospectively randomized German Breast Group (GBG)
trials of anthracycline-and taxane-based NACT were performed and analyzed in this study …
trials of anthracycline-and taxane-based NACT were performed and analyzed in this study …
Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline
S Gandhi, GG Fletcher, A Eisen, M Mates… - Current …, 2015 - pmc.ncbi.nlm.nih.gov
Background The Program in Evidence-Based Care (pebc) of Cancer Care Ontario recently
created an evidence-based consensus guideline on the systemic treatment of early breast …
created an evidence-based consensus guideline on the systemic treatment of early breast …
Neoadjuvant therapy–what have we achieved in the last 20 years
J Huober, G von Minckwitz - Breast Care, 2011 - karger.com
Neoadjuvant chemotherapy is the standard of care for patients with large, inoperable tumors
or inflammatory breast cancer, but it is also increasingly considered for women with …
or inflammatory breast cancer, but it is also increasingly considered for women with …
Model-based optimization of G-CSF treatment during cytotoxic chemotherapy
S Schirm, C Engel, S Loibl, M Loeffler… - Journal of Cancer …, 2018 - Springer
Abstract Purpose Although G-CSF is widely used to prevent or ameliorate leukopenia during
cytotoxic chemotherapies, its optimal use is still under debate and depends on many therapy …
cytotoxic chemotherapies, its optimal use is still under debate and depends on many therapy …
[PDF][PDF] Иммунная система и эффективность противоопухолевого лечения
НВ Чердынцева, ЮГ Кжышковска, МН Стахеева… - 2015 - vital.lib.tsu.ru
Повышение эффективности противоопухолевого лечения остается одной из наиболее
актуальных задач современной онкологии. Традиционно основной целью включения …
актуальных задач современной онкологии. Традиционно основной целью включения …
A proposal to redefine pathologic complete remission as endpoint following neoadjuvant chemotherapy in early breast cancer
M Dediu, C Zielinski - Breast care, 2020 - karger.com
Many analyses of the efficacy of neoadjuvant treatment (NAT) for early breast cancer
including a meta-analysis derived from 10 randomized trials came to the conclusion that …
including a meta-analysis derived from 10 randomized trials came to the conclusion that …
Preoperative therapy for operable breast cancer
Y Eralp - Breast Disease: Management and Therapies, Volume …, 2019 - Springer
Preoperative systemic chemotherapy (PSC), also known as “neoadjuvant chemotherapy,” is
an important therapy option for most patients with breast cancer. PSC has evolved as an …
an important therapy option for most patients with breast cancer. PSC has evolved as an …